Key facts
- Adrenomed’s last known valuation is $133.9M (Mar 2021).
- It has raised $61.3M; the latest was Later Stage VC ($770K) in May 2025.
- Notable investors include VU Venture Partners, Brandenburg Kapital, HBM Partners, Wellington Partners, KfW Group — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Adrenomed
- ·The full record, as it builds
Funding rounds
No funding rounds for Adrenomed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Adrenomed
Developer of clinical-stage pharmaceutical products designed to improve vascular integrity. The company's products use biomarker-guided monoclonal antibody therapies that offer a causative, safe treatment for acute circulatory failure, enabling doctors to reduce vascular leakage, stabilize the circulation, and lower mortality.
- Sector
- Healthcare
- HQ
- Hennigsdorf, Germany
- Founded
- 2009
- Employees
- 18
- Website
- adrenomed.com/
- Ownership
- Privately Held (backing)
Adrenomed doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Adrenomed shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Adrenomed in its N-PORT filings yet. We sweep new filings monthly.